Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
John Johnson, a director of Xeris Biopharma Holdings Inc (NASDAQ:XERS), sold 107,500 shares of common stock on August 13, 2025, according to a recent SEC Filing. The stock has shown remarkable strength, gaining over 175% in the past year and currently trades near its 52-week high of $7.61. The shares were sold at a weighted average price of $7.3159, for a total value of $786459.
The prices for the sale ranged from $7.250 to $7.420. Following the transaction, Johnson directly owns 833,483 shares of Xeris Biopharma Holdings.
In other recent news, Xeris Pharmaceuticals reported impressive earnings for the second quarter of 2025, surpassing analyst expectations. The company posted an earnings per share (EPS) of -0.01, beating the forecasted -0.03. Additionally, Xeris achieved a revenue of $71.5 million, exceeding projections by 11.85%. These results have highlighted strong investor confidence in the company. In another development, H.C. Wainwright has assumed coverage of Xeris Pharmaceuticals with a Buy rating and set a price target of $10.00. The firm noted the stock’s significant performance, having risen 108% year to date in 2025. These recent developments underscore the growing interest and positive outlook from analysts and investors alike.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.